Alexion Pharmaceuticals

Alexion Pharmaceuticals, an AstraZeneca Rare Disease company, develops and delivers life-changing therapies for individuals with rare diseases. The company leverages pioneering scientific research, particularly in complement biology, to address severe conditions lacking effective treatments. Its approach translates complex biological insights into transformative, often first-in-class, medicines for unmet medical needs.

Yale professor Leonard Bell founded Alexion in 1992. His insight was to create innovative solutions for devastating and ultra-rare disorders, addressing patient populations largely overlooked by conventional pharmaceutical research. He established the company to fill these therapeutic gaps, driven by a commitment to patients.

Alexion serves patients globally living with rare conditions impacting bone metabolism, hematology, and neurology. The company’s vision is to pioneer new possibilities for this community, striving to improve global patient outcomes. By integrating patient insights and collaborating with the rare disease ecosystem, Alexion advances research and expands access to specialized therapies.